Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-07-24

FDA Approved: DALVANCE — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for dalbavancin (DALVANCE) from Allergan, resulting in updated labeling for its approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dalvance (dalbavancin)

Snippet

SUPPL AP for DALVANCE (DALBAVANCIN)